1/199
Looks like no tags are added yet.
Prostate cancer is most common in who?
• Older males (>50 years old) • African Americans
The normal growth and differentiation of the prostate depends on the presence of androgens, specifically what?
dihydrotestosterone (DHT)
Exposure to androgens and chronic inflammation can lead to the development of neoplasm within the prostate cells known as
Prostatic Intraepithelial Neoplasia
GnRh agonists:
Leuprolide
Goserelin
Triptorelin
Histrelin
GnRH antagonist:
Degarelix
Relugolix
Clinical presentation of prostate cancer:
-urinary frequency
-nocturia
-straining
-hematuria
-ED or painful ejaculation
-Nocuria
-weak or slow urine stream
-Dysuria
-back, hip, or pelvis pain
-urinary urgency
-incontinence
-pain or discomfort while sitting
-fatigue
Risk factors for prostate cancer:
-Age older than 50 years old
-family hisotry
-lack of exercise
-obesity
-AA or carribean
-Family history of Breast cancer, ovarian cancer, lynch syndrome
-elevated test levels
-North american, NW europe, caribbean islands
-biologic males
-exposure to agent orange or cadmium
-multiple sex partners
-increased heigh
-western diet
-BRCA1/BRAC2, CHEK2
-hypertension
-decreased vitamin D etc.
Screening age for prostate cancer:
45 years old or 40 years old if high risk
Frequency of screening for prostate cancer:
q 1-2 years if normal or q 6 to 12 months if abnormal
d/c screening when for prostate cancer:
Life expectancy less than 10 years or up to greater than 75 years
Screening involves what?
Involves periodic PSA +/- Digital rectal examination (DRE) evaluations in selected men
High risk patients for prostate cancer:
*High risk: African American, men with first degree relative diagnosed with prostate cancer at age <65 years
• Searching for hard, nodular & irregular characteristics
Digital Rectal Exam (DRE)
• Protein made by both normal and cancer cells in the prostate gland • PSA level in the blood strongly correlates with risk and outcome • Many factors may affect PSA levels and should be taken into consideration
Prostate Specific Antigen
Genetic mutations for prostate cancer:
• E.g. BRCA1 and BRCA2
Imaging Tests for prostate cancer:
Transrectal ultrasound (TRUS) • Magnetic resonance imaging (MRI) • Bone scan • Indicated for more severe cases or cancer progression (PSA ≥ 20, Gleason Grade 4 & 5) • Computed tomography (CT) scan • Difficult to detect soft tissues and lymph nodes vs MRI
Serine protease enzyme produced by normal cells and cancer cells in the prostate
-Functions to break down large proteins found in semen to reduce viscosity and improve sperm function and fertility
PSA
Normal PSA:
1-1.5 ng/mL
Abnormal PSA:
greater than 3 ng/mL
PSA level with 50% increase in prostate cancer:
PSA Level > 10 ng/mL =
Increased PSA cause:
•Prostate Cancer •BPH •Prostatitis
•Ejaculation
•Trauma: DRE, TRUS, Biopsy
Decreased PSA cause:
•5-Alpha Reductase Inhibitors •Prostatectomy
•Prostate Radiation
•Anti-Androgen Therapy
Gold standard for prostate biopsy:
•Gold Standard: 12-Core Needle Biopsy with Transrectal Ultrasound Guidance (TRUS)
•Required to confirm diagnosis of prostate cancer
Prostate biopsy
•Used to evaluate and histopathology of prostate cancer and stratify based on risk •Based on how abnormal the cancer looks under microscope (well differentiated vs poorly differentiated)
Gleason score
• Clinically unapparent tumor, neither palpable nor visible by imaging
T1A
• Tumor confined within prostate
T2B
• Tumor extends through prostate capsule and may invade the seminal vesicles
T3C
• Tumor invades adjacentstructures(e.g., bladder)
T4D
Goal for Localized disease
Curative
Goal for Regional and Metastatic disease
Palliative
Goal Serum Testosterone Level
Castration: < 50 ng/dl within 1 month of therapy
Treatment for localized prostate cancer is based on
on the patient's recurrence risk group and their expected survival
Risk stratification groups are based on:
• Stage of cancer
• Gleason (pathologic tumor) Grade
• PSA leve
Recurrent advanced prostate castrate sensitive treatment:
Castrate Sensitive (Biochemical Recurrence) (m0CSPC)
Recurrent advanced prostate castrate resistant treatment:
Castrate Resistant (Non - Metastatic) (m0CRPC)
Metastatic castrate sensitive treatment:
(m1CSPC)
Metastatic castrate resistant treatment:
(m1CRPC)
Castrate Resistant:
Prostate cancer progression despite testosterone level < 50 ng/dL
Castrate RESISTANT Metastatic Prostate Cancer preferred regimen:
-abiraterone or
docetaxel or
enzalutamide
Abiraterone should be given with what?
corticosteroids (prednisone 5 mg BID)
Castrate RESISTANT Metastatic Prostate Cancer BRCA+
Niraparib + Abiraterone OR
Olaparib + abiraterone
Castrate RESISTANT Metastatic Prostate Cancer symptomatic bone metastases:
radium 223
Castrate RESISTANT Metastatic Prostate Cancer bone metastases:
denosumab 120 mg SQ every 4 weeks OR
Zoledronic acid 4 mg IV every 12 weeks
• Surgical procedure where one or both testicles are removed
Orchiectomy
Combined Androgen Blockade (CAB)
• LHRH Agonist + Anti-Androgen
Used as a method of reversible androgen ablation
LHRH agonist
Causes a surge in FSH, LH, and testosterone before suppression
LHRH agonist
Acute a/e for LHRH agonists:
-tumor flare
-gynecomastia
-hot flashes
-ED
-edema
-injection site reactions
Long term a/e for LHRH agonists:
-osteoporosis
-clinical fracture
-obesity
-insulin resistance
-alternation in lipids
-increased risk of DM and CV events
Zoladex
Goserelin
Lupron
Leuprolide
Trelstar
Triptorelin
Vantas
Histrelin
Firmagon
Degarelix
Orgovyx
Relugolix
Castrate levels are achieved in 7 days or less
LHRH antagonist
No tumor flare -> no need to give antiandrogens concomitantly
LHRH antagonist
Castrate levels are achieved in ~28 days
LHRH agonist
What may be most beneficial for preventing tumor flare, particularly in those with advanced metastatic disease
CAB
1st line metastatic castrate-sensitive treatment
GnRH agonist + 1st generation androgen
Symptoms caused by the initial induction of LH and FSH which causes a surge of testosterone
tumor flare
• Bone pain, tumor pain, urinary retention can be from what?
tumor flare
What can be used for prophylaxis of antiandrogens?
first generation anti-androgens such as bicalutamide, flutamide or nilutamide
LHRH agonist/antagonist a/e:
Symptoms are caused by the reduction in testosterone levels
Sexual dysfunction
• Loss of libido
• Impotence
Vasomotor symptoms
• Hot flashes,sweating, insomnia
• Rx: SSRI, estrogen,megestrol acetate, gabapentin
Increased risk for CV disease • Control risk factors; HLD, HTN, DM
• Anemia
Thinning of body hair Osteoporosis
All patients on ADT calcium and vitaminD supplement:
calcium 1000-1200 mg from food with supplements
-maintain serum vitamin D of 30-50 ng/mL with supplements
Lifestyle modifications for patients on ADT:
-weight exercise
-limit alcohol
-smoking cessation
A/E of bicultamide:
diarrhea and hematuria
BBW for nilutamide:
interstitial pneumonia
BBW or flutamide:
hepatic failure
Which 1st gen is preferred?
bicalutamide
What is the only 2nd generation anti-androgen that must be taken with food?
darolutamide
Inhibits CYP17 enzyme -> reduces the synthesis of testosterone
Abiraterone(Zytiga)
How to take Abiraterone:
• Take on an empty stomach, 2 hours before or 1 hour after meals • Food increases bioavailability
What should be taken with abiraterone?
• PLUS Prednisone 5 mg PO BID • Reduces the incidence and severity of side effects (hypertension, hypokalemia, and fluid retention) from increased mineraloco rticoids
A/E of Abiraterone:
• Mineralocorticoid excess
• Increase BP
• Decrease K
• Fluid retention
• Hepatic transaminitis (uncommon)
PH is a 72-year-old individual who was diagnosed with prostate cancer and is initiated on a hormone agent for the first time for androgen deprivation. Which of the following agents will result in castration levels of testosterone within 7 days?
A. Leuprolide
B. Goserelin
C. Triptorelin
D. Degarelix
D
Usually centrally located
Rapid and aggressive growth Distant metastases
SCLC
Centrally or peripherally located
Slower growing
NSCLC
Modifiable risk factors for NSCLC:
Smoking tobacco Occupational exposures Secondhand Smoke
Indoor and Outdoor Air Pollution
Treatment with radiation therapy
Beta-carotene use in smokers Smoking cannabis
Non-modifiable risk factors for NSCLC:
Family history of lung cancer
History of COPD, lung disease, TB, pulmonary fibrosis, and some infections
History of cancer, HIV, lupus, or weak immune system
Patient criteria for screening for lung cancer:
1. ≥50 years old
2. 20 Pack- year history*
-Pack year: number of cigs smoked per day/20 x number of years patient smoked
3. Current Smoker or quit in past 15 years
Pack year equation
- Pack years =
# of packs/day X # of years smoked
Stop screening when for lung cancer:
Stop screening when: - Patient has quit smoking for 15 years or
- Patients' health limits their life expectancy or ability for lung surgery
Clinical presentation of lung cancer:
Worsening cough
Wheeze
Chest pain
Hemoptysis
Malaise
Headache and face, arm, or neck swelling
Unexplained weight loss/ decreased appetite
Dyspnea
Hoarseness
Nightsweats
Fever
Arm,shoulder, and/or neck pain
_____ is the preferred first-line treatment for patients who are found to have select molecular and biomarker-directed therapy
Targeted therapy
Patients who have contraindications to immunotherapy should receive what?
chemotherapy without immunotherapy in the first-line setting
If no actionable mutations are found, then evaluate _____ status for consideration of immunotherapy single-agent or in combination with systemic chemotherapy
PD-L1
EGFR mutation drugs:
Osimertinib*,
Erlotinib, Afatinib, Gefitinib, Dacomitinib
KRAS mutation drugs:
Sotorasib
Adagrasib
ALK oncogene drugs:
Alectinib*,
Crizotinib
Ceritinib
Brigatinib
Lorlatinib*
ROS1 oncogene drugs:
Crizotinib, Ceritinib, Entrectinib, Repotrectinib
BRAF V600E mutation drugs:
Dabrafenib + Trametinib or Encorafenib + binimetinib
NTRK oncogene drugs:
Larotrectinib or Entrectinib
No mutation + PDL1 less than 50%:
Immunotherapy + Chemo
No mutation + PDL1 less than 50%+ squamous cell:
Carboplatin + Paclitaxel
No mutation + PDL1 less than 50%+ non-squamous cell:
Carboplatin + Pemetrexed or Carboplatin + Paclitaxel
No driver mutation + PDL1 greater than 50%
Monotherapy with Immunotherapy
Binding of EGF to EGFR activates what?
TK
EGFR Tyrosine Kinase Inhibitors (TKIs):
Osimertinib
Afatinib
Gefitinib